viewAnteris Technologies Ltd

Admedus board members stand with shareholders and buy shares

Current and former directors recently invested $700,000 in the company.

empty board room seats around a table
The company derives revenue from its ADAPT® and Infusion business divisions

Admedus Ltd (ASX:AHZ) has issued $200,000 worth of shares to three of its board members as part of the recent capital raising priced at 30 cents.

The share issuance required shareholder approval which was received at the extraordinary general meeting held yesterday.

Furthermore, a former director of the board Matthew Ratty was issued $500,000 worth of shares.

READ: Admedus raises $2.76 million from share purchase plan

Chairman John Seaberg purchased $50,000.10 of shares, president and CEO Wayne Paterson purchased $50,000.10, and non-executive director Simon Buckingham purchased $99,999.90.

READ: Admedus progressing towards securing $18 million investment for immunotherapies division

Admedus recently made progress towards securing a long-term funding arrangement for Admedus Vaccines Pty Ltd with Hong Kong investor Star Bright Holding Ltd by executing a Memorandum of Understanding (MoU).

In April, Admedus Vaccines entered into a Letter of Intent with Star Bright who paid a non-refundable break-fee of $500,000 to finalise the terms of an investment of $18 million.

The $18 million investment will be retained in the immunotherapies business to support ongoing research and development, as well as operational activities.

Quick facts: Anteris Technologies Ltd

Price: 3.9 AUD

Market: ASX
Market Cap: $23.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read